The U.S. veterinary medicine market size was estimated at USD 14.46 Billion in 2025 and is projected to reach USD 26.00 billion by 2033, growing at a CAGR of 7.6% from 2025 to 2033. The market growth is largely influenced by the rising global demand for animal protein, which increases the need for healthier livestock and efficient disease management. The growing incidence of animal diseases further amplifies the demand for effective diagnostic and treatment solutions. In addition, frequent product launches and innovations are enhancing the availability of advanced veterinary solutions, while continuous advancements in veterinary medicine are improving accuracy and outcomes in animal healthcare.
The market is continuously evolving due to research into novel product development, business expansion efforts, and strategic alliances to introduce innovative technologies. These efforts are reshaping market demand and practices. For instance, in February 2025, Align Capital Partners' pet health platform, Custom Veterinary Services (CVS), acquired Green Mountain Animal (GMA) to create a unified pet health products company called CompletePet. This merger is expected to offer a range of custom-formulated pet medicated feed additives and health products, with GMA's Vermont facility continuing to support innovation and supply chain capabilities.
Moreover, the growing trend of pet humanization has led pet owners to increasingly prioritize their pets’ health and well-being, driving a willingness to spend significantly more on their care. People are spending more on veterinary care and pet-related products, including premium food, medications, preventive checkups, vaccinations, surgeries, and even advanced treatments. According to the American Pet Products Association, U.S. spending on pets rose from $90.5 billion in 2018 to around $150.6 billion in 2024, an increase of 66%. Between 2018 and 2020, spending grew steadily by 14.5%, but the COVID-19 pandemic accelerated the trend, with a 45.4% jump from 2020 to 2024, largely due to more people adopting pets.
In addition, the FDA approval and subsequent U.S. launch of Zenrelia in September 2024 are playing a pivotal role in driving the growth of the veterinary medicine market by broadening the availability of advanced therapies for widespread yet difficult-to-manage conditions such as allergic and atopic dermatitis in dogs. Skin disorders are among the most frequent reasons for veterinary visits, and introduction of more effective therapy creates strong demand from both veterinarians and pet owners seeking better outcomes. Zenrelia works better than existing drugs such as Apoquel, which not only makes more veterinarians and pet owners choose it but also raises the standard for new treatments, encouraging more research and development in targeted therapies and precision medicine.
This product will be delivered within 2 business days.
The market is continuously evolving due to research into novel product development, business expansion efforts, and strategic alliances to introduce innovative technologies. These efforts are reshaping market demand and practices. For instance, in February 2025, Align Capital Partners' pet health platform, Custom Veterinary Services (CVS), acquired Green Mountain Animal (GMA) to create a unified pet health products company called CompletePet. This merger is expected to offer a range of custom-formulated pet medicated feed additives and health products, with GMA's Vermont facility continuing to support innovation and supply chain capabilities.
Moreover, the growing trend of pet humanization has led pet owners to increasingly prioritize their pets’ health and well-being, driving a willingness to spend significantly more on their care. People are spending more on veterinary care and pet-related products, including premium food, medications, preventive checkups, vaccinations, surgeries, and even advanced treatments. According to the American Pet Products Association, U.S. spending on pets rose from $90.5 billion in 2018 to around $150.6 billion in 2024, an increase of 66%. Between 2018 and 2020, spending grew steadily by 14.5%, but the COVID-19 pandemic accelerated the trend, with a 45.4% jump from 2020 to 2024, largely due to more people adopting pets.
In addition, the FDA approval and subsequent U.S. launch of Zenrelia in September 2024 are playing a pivotal role in driving the growth of the veterinary medicine market by broadening the availability of advanced therapies for widespread yet difficult-to-manage conditions such as allergic and atopic dermatitis in dogs. Skin disorders are among the most frequent reasons for veterinary visits, and introduction of more effective therapy creates strong demand from both veterinarians and pet owners seeking better outcomes. Zenrelia works better than existing drugs such as Apoquel, which not only makes more veterinarians and pet owners choose it but also raises the standard for new treatments, encouraging more research and development in targeted therapies and precision medicine.
U.S. Veterinary Medicine Market Report Segmentation
This report forecasts revenue growth provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. veterinary medicine market report based on product, animal type, route of administration, distribution channel:Product Outlook (Revenue, USD Million, 2021-2033)
- Biologics
- Pharmaceuticals
- Medicated Feed Additives
- Others
Animal Type Outlook (Revenue, USD Million, 2021-2033)
- Production Animals
- Companion Animals
Route of Administration Outlook (Revenue, USD Million, 2021-2033)
- Oral
- Injectable
- Topical
- Other Routes
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Veterinary Hospitals & Clinics
- E-commerce
- Offline Retail Stores
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Veterinary Medicine Market Variable Trends & Scope
Chapter 4. U.S. Veterinary Medicine Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Veterinary Medicine Market: Animal Type Estimates & Trend Analysis
Chapter 6. U.S. Veterinary Medicine Market: Route of Administration Estimates & Trend Analysis
Chapter 7. U.S. Veterinary Medicine Market: by Distribution Channel Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this U.S. Veterinary Medicine market report include:- Zoetis Inc.
- Boehringer Ingelheim International Gmbh
- Merck & Co., Inc.
- Elanco
- Dechra Pharmaceuticals PLC
- Ceva Santé Animale
- Phibro Animal Health Corporation
- Virbac
- Bimeda Corporate
- Biogénesis Bagó
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 14.46 Billion |
| Forecasted Market Value ( USD | $ 26 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
